Intracranial AneurysmsPLAQRANNCT03408379
Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN
An observational study of Intracranial Aneurysms and Ruptured Aneurysm, run by Fondation Ophtalmologique Adolphe de Rothschild at 1 site in France.
Trial summary
Sub arachnoid hemorrhage consecutive to intracranial aneurysm rupture is a devastating disease. Predictors of intracranial aneurysm rupture are limited and focus mainly on size and location. Platelet activation may have a deleterious role on aneurysm rupture. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Intracranial Aneurysms, Ruptured Aneurysm
- What is being tested?
- Collection of blood sample in aneurysm
- How many people
- 230 participants
- Where
- 1 siteFrance
- Study dates
- 20 Dec 2017to 23 Jun 2033
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients presenting a single or multiple intracranial aneurysm for which an intervention is planned (endovascular treatment or surgery)
Who may be able to join
- Patient aged 18 and over
- Patient presenting a single or multiple aneurysm
- Patient presenting an intracranial aneurysm for which an intervention is planned (endovascular treatment or surgery) : elective intervention for an unruptured aneurysm or emergency surgery for a broken aneurysm
Who cannot join
- Pregnant or breast feeding woman
- Patient benefiting from legal protection measures
Trial locations and contacts
1 site in 1 country.
About this study
Sub arachnoid hemorrhage consecutive to intracranial aneurysm rupture is a devastating disease. Predictors of intracranial aneurysm rupture are limited and focus mainly on size and location. Platelet activation may have a deleterious role on aneurysm rupture. The assumption is that patients with ruptured intracranial aneurysm will present a higher rate of platelet activation compared to patients with non ruptured aneurysms.
- Conditions
- Intracranial Aneurysms, Ruptured Aneurysm
- Being tested
- Collection of blood sample in aneurysm
- Keywords
- intracranial aneurysms, ruptured aneurysm, platelet activity
- Medical subject headings
- Intracranial Aneurysm, Aneurysm, Ruptured
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection of blood sample in aneurysmOther
In case of an endovascular treatment :
- A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.
- Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.
In case of a surgery treatment :
- A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.
- A Tissue sample will be taken during the surgery
- Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with platelet activation
comparison of this proportion between patients with ruptured versus non ruptured intracranial aneurysm
Measured: in the 7 days before embolisation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jan 2018
- Study start20 Dec 2017
- Primary completion23 Jun 2032 (estimated)
- Study completion23 Jun 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intracranial AneurysmsStudies of the same condition, open and under way.
- More trials run by Fondation Ophtalmologique Adolphe de RothschildThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 230 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Sponsor type
- Research network
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03408379
- Sponsor's protocol ID
- MMI_2017_27
- Acronym
- PLAQRAN
- Status last verified
- Jan 2026
- First submitted
- 17 Jan 2018
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN
- ClinicalTrials.gov ID
- NCT03408379
- Acronym / sponsor ID
- PLAQRAN / MMI_2017_27
- Conditions
- Intracranial Aneurysms, Ruptured Aneurysm
- Keywords
- intracranial aneurysms, ruptured aneurysm, platelet activity
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 230 participants (actual)
- Lead sponsor
- Fondation Ophtalmologique Adolphe de RothschildResearch network
- Study start
- 20 Dec 2017 (actual)
- Primary completion
- 23 Jun 2032 (estimated)
- Study completion
- 23 Jun 2033 (estimated)
- First posted
- 24 Jan 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sub arachnoid hemorrhage consecutive to intracranial aneurysm rupture is a devastating disease. Predictors of intracranial aneurysm rupture are limited and focus mainly on size and location. Platelet activation may have a deleterious role on aneurysm rupture. The assumption is that patients with ruptured intracranial aneurysm will present a higher rate of platelet activation compared to patients with non ruptured aneurysms.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients presenting a single or multiple intracranial aneurysm for which an intervention is planned (endovascular treatment or surgery)
Key inclusion criteria (3 listed)
- Patient aged 18 and over
- Patient presenting a single or multiple aneurysm
- Patient presenting an intracranial aneurysm for which an intervention is planned (endovascular treatment or surgery) : elective intervention for an unruptured aneurysm or emergency surgery for a broken aneurysm
Key exclusion criteria (2 listed)
- Pregnant or breast feeding woman
- Patient benefiting from legal protection measures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection of blood sample in aneurysmIn case of an endovascular treatment : * A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure. * Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit. In case of a surgery treatment : * A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery. * A Tissue sample will be taken during the surgery * Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit. | Other | – |
Primary outcome
Proportion of patients with platelet activation
Time frame: in the 7 days before embolisation
comparison of this proportion between patients with ruptured versus non ruptured intracranial aneurysm
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
Related trials for Intracranial Aneurysms
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingPhase 1/2
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Aneurysmal Subarachnoid Hemorrhage
RecruitingObservational study
A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms
Intracranial Aneurysm
Not yet recruiting
Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling
Intracranial Aneurysm, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intracranial Aneurysms and Ruptured Aneurysm, run by Fondation Ophtalmologique Adolphe de Rothschild at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients with platelet activation (time frame: in the 7 days before embolisation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.